Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview

GlobeNewswire August 9, 2022

Protara Therapeutics Announces Departure of Chief Financial Officer

GlobeNewswire June 21, 2022

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 26, 2022

Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations

GlobeNewswire May 12, 2022

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

GlobeNewswire May 5, 2022

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

GlobeNewswire March 24, 2022

Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

GlobeNewswire March 9, 2022

Protara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 2, 2022

Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference

GlobeNewswire February 1, 2022

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

GlobeNewswire January 10, 2022

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 4, 2022

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

GlobeNewswire November 4, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 25, 2021

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

GlobeNewswire October 12, 2021

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 17, 2021

Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition

GlobeNewswire September 13, 2021

Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

GlobeNewswire August 5, 2021